{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T13:54:21Z","timestamp":1791726861864,"version":"4.3.4"},"reference-count":55,"publisher":"e-Century Publishing Corporation","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Cancer Res"],"DOI":"10.62347\/rwlj3990","type":"journal-article","created":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T00:08:31Z","timestamp":1719533311000},"page":"2770-2789","source":"Crossref","is-referenced-by-count":7,"title":["mTOR inhibition by AZD2014 alleviates BCR::ABL1 independent imatinib resistance through enhancing autophagy in CML resistant cells"],"prefix":"10.62347","volume":"14","author":[{"given":"Wei","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"48694","published-online":{"date-parts":[[2024]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/306277a0","article-title":"Translocation of c-ab1 oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia","volume":"306","author":"Bartram","year":"1983","unstructured":"Bartram CR, de Klein A, Hagemeijer A, van Agthoven T, Geurts van Kessel A, Bootsma D, Grosveld G, Ferguson-Smith MA, Davies T and Stone M. Translocation of c-ab1 oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature 1983; 306: 277-280.","journal-title":"Nature"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1016\/S0140-6736(21)01204-6","article-title":"Chronic myeloid leukaemia","volume":"398","author":"Cortes","year":"2021","unstructured":"Cortes J, Pavlovsky C and Saußele S. Chronic myeloid leukaemia. Lancet 2021; 398: 1914-1926.","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12943-018-0780-6","article-title":"Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy","volume":"17","author":"Soverini","year":"2018","unstructured":"Soverini S, Mancini M, Bavaro L, Cavo M and Martinelli G. Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy. Mol Cancer 2018; 17: 49.","journal-title":"Mol Cancer"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1126\/science.3460176","article-title":"The chronic myelogenous leukemia-specific P210 protein is the product of the BCR\/ABL hybrid gene","volume":"233","author":"Ben-Neriah","year":"1986","unstructured":"Ben-Neriah Y, Daley GQ, Mes-Masson AM, Witte ON and Baltimore D. The chronic myelogenous leukemia-specific P210 protein is the product of the BCR\/ABL hybrid gene. Science 1986; 233: 212-214.","journal-title":"Science"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.ccell.2020.03.006","article-title":"Response and resistance to BCR-ABL1-targeted therapies","volume":"37","author":"TP","year":"2020","unstructured":"Braun TP, Eide CA and Druker BJ. Response and resistance to BCR-ABL1-targeted therapies. Cancer Cell 2020; 37: 530-542.","journal-title":"Cancer Cell"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1038\/leu.2008.221","article-title":"Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase","volume":"22","author":"Cortes","year":"2008","unstructured":"Cortes J, Kim DW, Raffoux E, Martinelli G, Ritchie E, Roy L, Coutre S, Corm S, Hamerschlak N, Tang JL, Hochhaus A, Khoury HJ, Brümmendorf TH, Michallet M, Rege-Cambrin G, Gambacorti-Passerini C, Radich JP, Ernst T, Zhu C, Van Tornout JM and Talpaz M. Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase. Leukemia 2008; 22: 2176-2183.","journal-title":"Leukemia"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"939","DOI":"10.3389\/fonc.2019.00939","article-title":"BCR-ABL independent mechanisms of resistance in chronic myeloid leukemia","volume":"9","author":"Loscocco","year":"2019","unstructured":"Loscocco F, Visani G, Galimberti S, Curti A and Isidori A. BCR-ABL independent mechanisms of resistance in chronic myeloid leukemia. Front Oncol 2019; 9: 939.","journal-title":"Front Oncol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41467-020-20259-0","article-title":"Targeting USP47 overcomes tyrosine kinase inhibitor resistance and eradicates leukemia stem\/progenitor cells in chronic myelogenous leukemia","volume":"12","author":"Lei","year":"2021","unstructured":"Lei H, Xu HZ, Shan HZ, Liu M, Lu Y, Fang ZX, Jin J, Jing B, Xiao XH, Gao SM, Gao FH, Xia L, Yang L, Liu LG, Wang WW, Liu CX, Tong Y, Wu YZ, Zheng JK, Chen GQ, Zhou L and Wu YL. Targeting USP47 overcomes tyrosine kinase inhibitor resistance and eradicates leukemia stem\/progenitor cells in chronic myelogenous leukemia. Nat Commun 2021; 12: 51.","journal-title":"Nat Commun"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s13045-016-0359-x","article-title":"Nickel pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via both BCR\/ABL-dependent and BCR\/ABL-independent mechanisms","volume":"9","author":"Lan","year":"2016","unstructured":"Lan X, Zhao C, Chen X, Zhang P, Zang D, Wu J, Chen J, Long H, Yang L, Huang H, Carter BZ, Wang X, Shi X and Liu J. Nickel pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via both BCR\/ABL-dependent and BCR\/ABL-independent mechanisms. J Hematol Oncol 2016; 9: 129.","journal-title":"J Hematol Oncol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1182\/blood.V83.6.1575.1575","article-title":"Expression of BCR-ABL abrogates factor-dependent growth of human hematopoietic M07E cells by an autocrine mechanism","volume":"83","author":"Sirard","year":"1994","unstructured":"Sirard C, Laneuville P and Dick JE. Expression of BCR-ABL abrogates factor-dependent growth of human hematopoietic M07E cells by an autocrine mechanism. Blood 1994; 83: 1575-1585.","journal-title":"Blood"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Ma L, Shan Y, Bai R, Xue L, Eide CA, Ou J, Zhu LJ, Hutchinson L, Cerny J, Khoury HJ, Sheng Z, Druker BJ, Li S and Green MR. A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia. Sci Transl Med 2014; 6: 252ra121.","DOI":"10.1126\/scitranslmed.3009073"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/s41392-023-01608-z","article-title":"Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease","volume":"8","author":"Panwar","year":"2023","unstructured":"Panwar V, Singh A, Bhatt M, Tonk RK, Azizov S, Raza AS, Sengupta S, Kumar D and Garg M. Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease. Signal Transduct Target Ther 2023; 8: 375.","journal-title":"Signal Transduct Target Ther"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13045-019-0754-1","article-title":"Targeting mTOR for cancer therapy","volume":"12","author":"Hua","year":"2019","unstructured":"Hua H, Kong Q, Zhang H, Wang J, Luo T and Jiang Y. Targeting mTOR for cancer therapy. J Hematol Oncol 2019; 12: 71.","journal-title":"J Hematol Oncol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1186\/1471-2407-13-250","article-title":"Characteristic mTOR activity in Hodgkin-lymphomas offers a potential therapeutic target in high risk disease--a combined tissue microarray, in vitro and in vivo study","volume":"13","author":"M&#xE1","year":"2013","unstructured":"Márk Á, Hajdu M, Váradi Z, Sticz TB, Nagy N, Csomor J, Berczi L, Varga V, Csóka M, Kopper L and Sebestyén A. Characteristic mTOR activity in Hodgkin-lymphomas offers a potential therapeutic target in high risk disease--a combined tissue microarray, in vitro and in vivo study. BMC Cancer 2013; 13: 250.","journal-title":"BMC Cancer"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.semcancer.2019.07.003","article-title":"mTOR: role in cancer, metastasis and drug resistance","volume":"59","author":"Murugan","year":"2019","unstructured":"Murugan AK. mTOR: role in cancer, metastasis and drug resistance. Semin Cancer Biol 2019; 59: 92-111.","journal-title":"Semin Cancer Biol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"655731","DOI":"10.3389\/fcell.2021.655731","article-title":"The mTOR-autophagy axis and the control of metabolism","volume":"9","author":"Deleyto-Seldas","year":"2021","unstructured":"Deleyto-Seldas N and Efeyan A. The mTOR-autophagy axis and the control of metabolism. Front Cell Dev Biol 2021; 9: 655731.","journal-title":"Front Cell Dev Biol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"118643","DOI":"10.1016\/j.lfs.2020.118643","article-title":"Effects of rapamycin and AZD3463 combination on apoptosis, autophagy, and cell cycle for resistance control in breast cancer","volume":"264","author":"NP","year":"2021","unstructured":"Ozates NP, Soğutlu F, Lerminoglu F, Demir B, Gunduz C, Shademan B and Avci CB. Effects of rapamycin and AZD3463 combination on apoptosis, autophagy, and cell cycle for resistance control in breast cancer. Life Sci 2021; 264: 118643.","journal-title":"Life Sci"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"An JY, Kerns KA, Ouellette A, Robinson L, Morris HD, Kaczorowski C, Park SI, Mekvanich T, Kang A, McLean JS, Cox TC and Kaeberlein M. Rapamycin rejuvenates oral health in aging mice. Elife 2020; 9: e54318.","DOI":"10.7554\/eLife.54318"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.cmet.2014.01.001","article-title":"Rapamycin: one drug, many effects","volume":"19","author":"Li","year":"2014","unstructured":"Li J, Kim SG and Blenis J. Rapamycin: one drug, many effects. Cell Metab 2014; 19: 373-379.","journal-title":"Cell Metab"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1080\/15548627.2020.1822628","article-title":"The role of autophagy in targeted therapy for acute myeloid leukemia","volume":"17","author":"Du","year":"2021","unstructured":"Du W, Xu A, Huang Y, Cao J, Zhu H, Yang B, Shao X, He Q and Ying M. The role of autophagy in targeted therapy for acute myeloid leukemia. Autophagy 2021; 17: 2665-2679.","journal-title":"Autophagy"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1038\/sj.leu.2403898","article-title":"Compensatory PI3-kinase\/Akt\/mTOR activation regulates imatinib resistance development","volume":"19","author":"Burchert","year":"2005","unstructured":"Burchert A, Wang Y, Cai D, von Bubnoff N, Paschka P, Müller-Brüsselbach S, Ottmann OG, Duyster J, Hochhaus A and Neubauer A. Compensatory PI3-kinase\/Akt\/mTOR activation regulates imatinib resistance development. Leukemia 2005; 19: 1774-1782.","journal-title":"Leukemia"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1093\/jnci\/djx236","article-title":"Targeting BCR-ABL-independent TKI resistance in chronic myeloid leukemia by mTOR and autophagy inhibition","volume":"110","author":"Mitchell","year":"2018","unstructured":"Mitchell R, Hopcroft LEM, Baquero P, Allan EK, Hewit K, James D, Hamilton G, Mukhopadhyay A, O’Prey J, Hair A, Melo JV, Chan E, Ryan KM, Maguer-Satta V, Druker BJ, Clark RE, Mitra S, Herzyk P, Nicolini FE, Salomoni P, Shanks E, Calabretta B, Holyoake TL and Helgason GV. Targeting BCR-ABL-independent TKI resistance in chronic myeloid leukemia by mTOR and autophagy inhibition. J Natl Cancer Inst 2018; 110: 467-478.","journal-title":"J Natl Cancer Inst"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1093\/neuonc\/not139","article-title":"The mTORC1\/mTORC2 inhibitor AZD2014 enhances the radiosensitivity of glioblastoma stem-like cells","volume":"16","author":"Kahn","year":"2014","unstructured":"Kahn J, Hayman TJ, Jamal M, Rath BH, Kramp T, Camphausen K and Tofilon PJ. The mTORC1\/mTORC2 inhibitor AZD2014 enhances the radiosensitivity of glioblastoma stem-like cells. Neuro Oncol 2014; 16: 29-37.","journal-title":"Neuro Oncol"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Milošević Z, Banković J, Dinić J, Tsimplouli C, Sereti E, Dragoj M, Paunović V, Milovanović Z, Stepanović M, Tanić N, Dimas K and Pešić M. Potential of the dual mTOR kinase inhibitor AZD2014 to overcome paclitaxel resistance in anaplastic thyroid carcinoma. Cell Oncol (Dordr) 2018; 41: 409-426.","DOI":"10.1007\/s13402-018-0380-x"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1158\/2159-8290.CD-19-0442","article-title":"Tumor genomic profiling guides patients with metastatic gastric cancer to targeted treatment: the VIKTORY umbrella trial","volume":"9","author":"Lee","year":"2019","unstructured":"Lee J, Kim ST, Kim K, Lee H, Kozarewa I, Mortimer PGS, Odegaard JI, Harrington EA, Lee J, Lee T, Oh SY, Kang JH, Kim JH, Kim Y, Ji JH, Kim YS, Lee KE, Kim J, Sohn TS, An JY, Choi MG, Lee JH, Bae JM, Kim S, Kim JJ, Min YW, Min BH, Kim NKD, Luke S, Kim YH, Hong JY, Park SH, Park JO, Park YS, Lim HY, Talasaz A, Hollingsworth SJ, Kim KM and Kang WK. Tumor genomic profiling guides patients with metastatic gastric cancer to targeted treatment: the VIKTORY umbrella trial. Cancer Discov 2019; 9: 1388-1405.","journal-title":"Cancer Discov"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1002\/ijc.2910180405","article-title":"Properties of the K562 cell line, derived from a patient with chronic myeloid leukemia","volume":"18","author":"Klein","year":"1976","unstructured":"Klein E, Ben-Bassat H, Neumann H, Ralph P, Zeuthen J, Polliack A and Vánky F. Properties of the K562 cell line, derived from a patient with chronic myeloid leukemia. Int J Cancer 1976; 18: 421-431.","journal-title":"Int J Cancer"},{"key":"ref26","unstructured":"Tang HM, Ding W, Ding YH, Wu JJ and Li YF. Effects of ubiquitination on the expression of BCL6 protein, cell proliferation and apoptosis in K562\/G01 cells. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2019; 27: 379-384."},{"key":"ref27","unstructured":"Zhu Hl, Liu T, Meng WT and Jia YQ. Establishment of an imatinib resistance cell line K562R and its resistant principia. Sichuan Da Xue Xue Bao Yi Xue Ban 2007; 38: 22-26."},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1182\/blood.V96.3.1070","article-title":"Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance","volume":"96","author":"Mahon","year":"2000","unstructured":"Mahon FX, Deininger MW, Schultheis B, Chabrol J, Reiffers J, Goldman JM and Melo JV. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 2000; 96: 1070-1079.","journal-title":"Blood"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/978-1-4939-0888-2_7","article-title":"Cell cycle regulation by the nutrient-sensing mammalian target of rapamycin (mTOR) pathway","volume":"1170","author":"Cuy&#xE0","year":"2014","unstructured":"Cuyàs E, Corominas-Faja B, Joven J and Menendez JA. Cell cycle regulation by the nutrient-sensing mammalian target of rapamycin (mTOR) pathway. Methods Mol Biol 2014; 1170: 113-144.","journal-title":"Methods Mol Biol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.1128\/MCB.19.4.2690","article-title":"NF-kappaB function in growth control: regulation of cyclin D1 expression and G0\/G1-to-S-phase transition","volume":"19","author":"Hinz","year":"1999","unstructured":"Hinz M, Krappmann D, Eichten A, Heder A, Scheidereit C and Strauss M. NF-kappaB function in growth control: regulation of cyclin D1 expression and G0\/G1-to-S-phase transition. Mol Cell Biol 1999; 19: 2690-2698.","journal-title":"Mol Cell Biol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1038\/s41419-023-05763-7","article-title":"Aberrant Cyclin D1 splicing in cancer: from molecular mechanism to therapeutic modulation","volume":"14","author":"Wang","year":"2023","unstructured":"Wang J, Su W, Zhang T, Zhang S, Lei H, Ma F, Shi M, Shi W, Xie X and Di C. Aberrant Cyclin D1 splicing in cancer: from molecular mechanism to therapeutic modulation. Cell Death Dis 2023; 14: 244.","journal-title":"Cell Death Dis"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"70","DOI":"10.4161\/auto.26534","article-title":"Hypoxia-induced MIR155 is a potent autophagy inducer by targeting multiple players in the MTOR pathway","volume":"10","author":"Wan","year":"2014","unstructured":"Wan G, Xie W, Liu Z, Xu W, Lao Y, Huang N, Cui K, Liao M, He J, Jiang Y, Yang BB, Xu H, Xu N and Zhang Y. Hypoxia-induced MIR155 is a potent autophagy inducer by targeting multiple players in the MTOR pathway. Autophagy 2014; 10: 70-79.","journal-title":"Autophagy"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1016\/j.jacc.2009.08.031","article-title":"Beneficial effects of Mammalian target of rapamycin inhibition on left ventricular remodeling after myocardial infarction","volume":"54","author":"Buss","year":"2009","unstructured":"Buss SJ, Muenz S, Riffel JH, Malekar P, Hagenmueller M, Weiss CS, Bea F, Bekeredjian R, Schinke-Braun M, Izumo S, Katus HA and Hardt SE. Beneficial effects of Mammalian target of rapamycin inhibition on left ventricular remodeling after myocardial infarction. J Am Coll Cardiol 2009; 54: 2435-2446.","journal-title":"J Am Coll Cardiol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1111\/j.1474-9726.2012.00833.x","article-title":"Fibroblasts from long-lived mutant mice exhibit increased autophagy and lower TOR activity after nutrient deprivation or oxidative stress","volume":"11","author":"Wang","year":"2012","unstructured":"Wang M and Miller RA. Fibroblasts from long-lived mutant mice exhibit increased autophagy and lower TOR activity after nutrient deprivation or oxidative stress. Aging Cell 2012; 11: 668-674.","journal-title":"Aging Cell"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13046-022-02298-1","article-title":"FAM167A is a key molecule to induce BCR-ABL-independent TKI resistance in CML via noncanonical NF-κB signaling activation","volume":"41","author":"Yang","year":"2022","unstructured":"Yang T, Sim KY, Ko GH, Ahn JS, Kim HJ and Park SG. FAM167A is a key molecule to induce BCR-ABL-independent TKI resistance in CML via noncanonical NF-κB signaling activation. J Exp Clin Cancer Res 2022; 41: 82.","journal-title":"J Exp Clin Cancer Res"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"6312","DOI":"10.1002\/jcp.30301","article-title":"PKC-β\/Alox5 axis activation promotes BCR-ABL-independent TKI-resistance in chronic myeloid leukemia","volume":"236","author":"Ma","year":"2021","unstructured":"Ma D, Liu P, Wang P, Zhou Z, Fang Q and Wang J. PKC-β\/Alox5 axis activation promotes BCR-ABL-independent TKI-resistance in chronic myeloid leukemia. J Cell Physiol 2021; 236: 6312-6327.","journal-title":"J Cell Physiol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1007\/s00018-015-1867-5","article-title":"Targeting PI3K\/AKT\/mTOR network for treatment of leukemia","volume":"72","author":"Bertacchini","year":"2015","unstructured":"Bertacchini J, Heidari N, Mediani L, Capitani S, Shahjahani M, Ahmadzadeh A and Saki N. Targeting PI3K\/AKT\/mTOR network for treatment of leukemia. Cell Mol Life Sci 2015; 72: 2337-2347.","journal-title":"Cell Mol Life Sci"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"102268","DOI":"10.1016\/j.redox.2022.102268","article-title":"mTOR inhibition downregulates glucose-6-phosphate dehydrogenase and induces ROS-dependent death in T-cell acute lymphoblastic leukemia cells","volume":"51","author":"Silic-Benussi M","year":"2022","unstructured":"Silic-Benussi M, Sharova E, Ciccarese F, Cavallari I, Raimondi V, Urso L, Corradin A, Kotler H, Scattolin G, Buldini B, Francescato S, Basso G, Minuzzo SA, Indraccolo S, D’Agostino DM and Ciminale V. mTOR inhibition downregulates glucose-6-phosphate dehydrogenase and induces ROS-dependent death in T-cell acute lymphoblastic leukemia cells. Redox Biol 2022; 51: 102268.","journal-title":"Redox Biol"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1172\/JCI73939","article-title":"mTOR: a pharmacologic target for autophagy regulation","volume":"125","author":"Kim","year":"2015","unstructured":"Kim YC and Guan KL. mTOR: a pharmacologic target for autophagy regulation. J Clin Invest 2015; 125: 25-32.","journal-title":"J Clin Invest"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"4684","DOI":"10.1038\/s41467-020-18504-7","article-title":"mTOR-mediated cancer drug resistance suppresses autophagy and generates a druggable metabolic vulnerability","volume":"11","author":"Gremke","year":"2020","unstructured":"Gremke N, Polo P, Dort A, Schneikert J, Elmshäuser S, Brehm C, Klingmüller U, Schmitt A, Reinhardt HC, Timofeev O, Wanzel M and Stiewe T. mTOR-mediated cancer drug resistance suppresses autophagy and generates a druggable metabolic vulnerability. Nat Commun 2020; 11: 4684.","journal-title":"Nat Commun"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1080\/15548627.2015.1040976","article-title":"ATG12-ATG3 connects basal autophagy and late endosome function","volume":"11","author":"Murrow","year":"2015","unstructured":"Murrow L and Debnath J. ATG12-ATG3 connects basal autophagy and late endosome function. Autophagy 2015; 11: 961-962.","journal-title":"Autophagy"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"928","DOI":"10.3390\/antiox10060928","article-title":"Green tea polyphenol catechins inhibit coronavirus replication and potentiate the adaptive immunity and autophagy-dependent protective mechanism to improve acute lung injury in mice","volume":"10","author":"Yang","year":"2021","unstructured":"Yang CC, Wu CJ, Chien CY and Chien CT. Green tea polyphenol catechins inhibit coronavirus replication and potentiate the adaptive immunity and autophagy-dependent protective mechanism to improve acute lung injury in mice. Antioxidants (Basel) 2021; 10: 928.","journal-title":"Antioxidants (Basel)"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"Pareek G and Kundu M. Physiological functions of ULK1\/2. J Mol Biol 2024; 168472.","DOI":"10.1016\/j.jmb.2024.168472"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.tcb.2010.03.002","article-title":"The Beclin 1-VPS34 complex--at the crossroads of autophagy and beyond","volume":"20","author":"SF","year":"2010","unstructured":"Funderburk SF, Wang QJ and Yue Z. The Beclin 1-VPS34 complex--at the crossroads of autophagy and beyond. Trends Cell Biol 2010; 20: 355-362.","journal-title":"Trends Cell Biol"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"4323","DOI":"10.1080\/15548627.2021.1912270","article-title":"CUL3 (cullin 3)-mediated ubiquitination and degradation of BECN1 (beclin 1) inhibit autophagy and promote tumor progression","volume":"17","author":"Li","year":"2021","unstructured":"Li X, Yang KB, Chen W, Mai J, Wu XQ, Sun T, Wu RY, Jiao L, Li DD, Ji J, Zhang HL, Yu Y, Chen YH, Feng GK, Deng R, Li JD and Zhu XF. CUL3 (cullin 3)-mediated ubiquitination and degradation of BECN1 (beclin 1) inhibit autophagy and promote tumor progression. Autophagy 2021; 17: 4323-4340.","journal-title":"Autophagy"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1038\/onc.2010.561","article-title":"Autophagy is essential to suppress cell stress and to allow BCR-ABL-mediated leukemogenesis","volume":"30","author":"Altman","year":"2011","unstructured":"Altman BJ, Jacobs SR, Mason EF, Michalek RD, MacIntyre AN, Coloff JL, Ilkayeva O, Jia W, He YW and Rathmell JC. Autophagy is essential to suppress cell stress and to allow BCR-ABL-mediated leukemogenesis. Oncogene 2011; 30: 1855-1867.","journal-title":"Oncogene"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1172\/JCI35660","article-title":"Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells","volume":"119","author":"Bellodi","year":"2009","unstructured":"Bellodi C, Lidonnici MR, Hamilton A, Helgason GV, Soliera AR, Ronchetti M, Galavotti S, Young KW, Selmi T, Yacobi R, Van Etten RA, Donato N, Hunter A, Dinsdale D, Tirrò E, Vigneri P, Nicotera P, Dyer MJ, Holyoake T, Salomoni P and Calabretta B. Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells. J Clin Invest 2009; 119: 1109-1123.","journal-title":"J Clin Invest"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1182\/blood-2011-01-330621","article-title":"Kill one bird with two stones: potential efficacy of BCR-ABL and autophagy inhibition in CML","volume":"118","author":"GV","year":"2011","unstructured":"Helgason GV, Karvela M and Holyoake TL. Kill one bird with two stones: potential efficacy of BCR-ABL and autophagy inhibition in CML. Blood 2011; 118: 2035-2043.","journal-title":"Blood"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1080\/15548627.2016.1162359","article-title":"ATG7 regulates energy metabolism, differentiation and survival of Philadelphia-chromosome-positive cells","volume":"12","author":"Karvela","year":"2016","unstructured":"Karvela M, Baquero P, Kuntz EM, Mukhopadhyay A, Mitchell R, Allan EK, Chan E, Kranc KR, Calabretta B, Salomoni P, Gottlieb E, Holyoake TL and Helgason GV. ATG7 regulates energy metabolism, differentiation and survival of Philadelphia-chromosome-positive cells. Autophagy 2016; 12: 936-948.","journal-title":"Autophagy"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"2840","DOI":"10.1182\/blood-2010-12-322537","article-title":"BCR-ABL suppresses autophagy through ATF5-mediated regulation of mTOR transcription","volume":"118","author":"Sheng","year":"2011","unstructured":"Sheng Z, Ma L, Sun JE, Zhu LJ and Green MR. BCR-ABL suppresses autophagy through ATF5-mediated regulation of mTOR transcription. Blood 2011; 118: 2840-2848.","journal-title":"Blood"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1038\/leu.2012.65","article-title":"Targeting microRNA-30a-mediated autophagy enhances imatinib activity against human chronic myeloid leukemia cells","volume":"26","author":"Yu","year":"2012","unstructured":"Yu Y, Yang L, Zhao M, Zhu S, Kang R, Vernon P, Tang D and Cao L. Targeting microRNA-30a-mediated autophagy enhances imatinib activity against human chronic myeloid leukemia cells. Leukemia 2012; 26: 1752-1760.","journal-title":"Leukemia"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"3852","DOI":"10.1093\/hmg\/ddr306","article-title":"Characterization of the CLEAR network reveals an integrated control of cellular clearance pathways","volume":"20","author":"Palmieri","year":"2011","unstructured":"Palmieri M, Impey S, Kang H, di Ronza A, Pelz C, Sardiello M and Ballabio A. Characterization of the CLEAR network reveals an integrated control of cellular clearance pathways. Hum Mol Genet 2011; 20: 3852-3866.","journal-title":"Hum Mol Genet"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1080\/15548627.2022.2105561","article-title":"Regulation of TFEB nuclear localization by HSP90AA1 promotes autophagy and longevity","volume":"19","author":"Yang","year":"2023","unstructured":"Yang S, Nie T, She H, Tao K, Lu F, Hu Y, Huang L, Zhu L, Feng D, He D, Qi J, Kukar T, Ma L, Mao Z and Yang Q. Regulation of TFEB nuclear localization by HSP90AA1 promotes autophagy and longevity. Autophagy 2023; 19: 822-838.","journal-title":"Autophagy"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1002\/cpt.2699","article-title":"Exposure-efficacy analysis of asciminib in philadelphia chromosome-positive chronic myeloid leukemia in chronic phase","volume":"112","author":"Combes","year":"2022","unstructured":"Combes FP, Li YF, Hoch M, Lorenzo S, Ho YY and Sy SKB. Exposure-efficacy analysis of asciminib in philadelphia chromosome-positive chronic myeloid leukemia in chronic phase. Clin Pharmacol Ther 2022; 112: 1040-1050.","journal-title":"Clin Pharmacol Ther"}],"container-title":["American Journal of Cancer Research"],"original-title":[],"link":[{"URL":"https:\/\/e-century.us\/files\/ajcr\/14\/6\/ajcr0155948.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T01:53:53Z","timestamp":1766022833000},"score":1,"resource":{"primary":{"URL":"https:\/\/e-century.us\/files\/ajcr\/14\/6\/ajcr0155948.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":55,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.62347\/rwlj3990","relation":{},"ISSN":["2156-6976"],"issn-type":[{"value":"2156-6976","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024]]}}}